Annual CFF
$558.34 M
+$324.73 M+139.00%
December 31, 2023
Summary
- As of February 12, 2025, IBRX annual cash flow from financing activities is $558.34 million, with the most recent change of +$324.73 million (+139.00%) on December 31, 2023.
- During the last 3 years, IBRX annual CFF has risen by +$407.67 million (+270.56%).
- IBRX annual CFF is now at all-time high.
Performance
IBRX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$15.58 M
-$133.31 M-89.53%
September 30, 2024
Summary
- As of February 12, 2025, IBRX quarterly cash flow from financing activities is $15.58 million, with the most recent change of -$133.31 million (-89.53%) on September 30, 2024.
- Over the past year, IBRX quarterly CFF has dropped by -$133.31 million (-89.53%).
- IBRX quarterly CFF is now -95.22% below its all-time high of $325.95 million, reached on December 31, 2021.
Performance
IBRX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$375.24 M
-$221.92 M-37.16%
September 30, 2024
Summary
- As of February 12, 2025, IBRX TTM cash flow from financing activities is $375.24 million, with the most recent change of -$221.92 million (-37.16%) on September 30, 2024.
- Over the past year, IBRX TTM CFF has dropped by -$221.92 million (-37.16%).
- IBRX TTM CFF is now -37.16% below its all-time high of $597.16 million, reached on June 30, 2024.
Performance
IBRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
IBRX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +139.0% | -89.5% | -37.2% |
| 3 y3 years | +270.6% | -64.1% | +5.9% |
| 5 y5 years | +388.6% | -64.1% | +5.9% |
IBRX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +139.0% | -95.2% | +5328.9% | -37.2% | +60.6% |
| 5 y | 5-year | at high | +388.6% | -95.2% | +5328.9% | -37.2% | >+9999.0% |
| alltime | all time | at high | +388.6% | -95.2% | +5328.9% | -37.2% | >+9999.0% |
ImmunityBio Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $15.58 M(-89.5%) | $375.24 M(-37.2%) |
| Jun 2024 | - | $148.89 M(+1356.2%) | $597.16 M(+21.5%) |
| Mar 2024 | - | $10.22 M(-94.9%) | $491.68 M(-11.9%) |
| Dec 2023 | $558.34 M(+139.0%) | $200.54 M(-15.6%) | $558.34 M(+19.4%) |
| Sep 2023 | - | $237.50 M(+447.1%) | $467.74 M(+32.0%) |
| Jun 2023 | - | $43.41 M(-43.5%) | $354.23 M(+14.0%) |
| Mar 2023 | - | $76.89 M(-30.1%) | $310.80 M(+33.0%) |
| Dec 2022 | $233.61 M | $109.94 M(-11.3%) | $233.61 M(-48.0%) |
| Sep 2022 | - | $123.99 M(<-9900.0%) | $449.63 M(+22.1%) |
| Jun 2022 | - | -$15.00 K(-95.0%) | $368.30 M(-21.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$298.00 K(-100.1%) | $466.65 M(-7.7%) |
| Dec 2021 | $505.44 M(+235.5%) | $325.95 M(+664.1%) | $505.44 M(+181.2%) |
| Sep 2021 | - | $42.66 M(-56.6%) | $179.73 M(-10.3%) |
| Jun 2021 | - | $98.34 M(+155.4%) | $200.29 M(+5.8%) |
| Mar 2021 | - | $38.50 M(>+9900.0%) | $189.29 M(+25.6%) |
| Dec 2020 | $150.68 M(+31.8%) | $241.00 K(-99.6%) | $150.68 M(+0.2%) |
| Sep 2020 | - | $63.22 M(-27.6%) | $150.43 M(+72.5%) |
| Jun 2020 | - | $87.34 M(<-9900.0%) | $87.22 M(<-9900.0%) |
| Mar 2020 | - | -$123.00 K | -$123.00 K |
| Dec 2019 | $114.28 M | - | - |
FAQ
- What is ImmunityBio annual cash flow from financing activities?
- What is the all time high annual CFF for ImmunityBio?
- What is ImmunityBio annual CFF year-on-year change?
- What is ImmunityBio quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for ImmunityBio?
- What is ImmunityBio quarterly CFF year-on-year change?
- What is ImmunityBio TTM cash flow from financing activities?
- What is the all time high TTM CFF for ImmunityBio?
- What is ImmunityBio TTM CFF year-on-year change?
What is ImmunityBio annual cash flow from financing activities?
The current annual CFF of IBRX is $558.34 M
What is the all time high annual CFF for ImmunityBio?
ImmunityBio all-time high annual cash flow from financing activities is $558.34 M
What is ImmunityBio annual CFF year-on-year change?
Over the past year, IBRX annual cash flow from financing activities has changed by +$324.73 M (+139.00%)
What is ImmunityBio quarterly cash flow from financing activities?
The current quarterly CFF of IBRX is $15.58 M
What is the all time high quarterly CFF for ImmunityBio?
ImmunityBio all-time high quarterly cash flow from financing activities is $325.95 M
What is ImmunityBio quarterly CFF year-on-year change?
Over the past year, IBRX quarterly cash flow from financing activities has changed by -$133.31 M (-89.53%)
What is ImmunityBio TTM cash flow from financing activities?
The current TTM CFF of IBRX is $375.24 M
What is the all time high TTM CFF for ImmunityBio?
ImmunityBio all-time high TTM cash flow from financing activities is $597.16 M
What is ImmunityBio TTM CFF year-on-year change?
Over the past year, IBRX TTM cash flow from financing activities has changed by -$221.92 M (-37.16%)